GeoVax Labs (GOVX) vs Matinas Biopharma (MTNB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
GeoVax Labs is the larger company by market cap ($2.9 million vs $2.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOVX | MTNB |
|---|---|---|
| Share price | $0.2866 | $2.83 |
| Market cap | $2.90M | $2.77M |
| 1-day change | -0.97% | +2.17% |
| EPS (TTM) | $-8.84 | $-17.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.75 | $28.95 |
| 52-week low | $0.277 | $2.27 |
| Distance from 52-week high | -98.18% | -90.22% |
| Analyst consensus | none | — |
| Avg. price target upside | +3389.18% | — |
| Average volume | 771.47K | 405.99K |
| Shares outstanding | 10.10M | 979.52K |
| Employees | 19 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GeoVax Labs
GOVX stock →GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Healthcare · Biotechnology · 19 employees
About Matinas Biopharma
MTNB stock →Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Healthcare · Biotechnology · 2 employees
GOVX vs MTNB FAQ
Which is bigger, GeoVax Labs or Matinas Biopharma?
GeoVax Labs (GOVX) is larger, with a market capitalization of $2.90M compared with $2.77M for Matinas Biopharma (MTNB).
Are GeoVax Labs and Matinas Biopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.